ESMO Congress 2026

A Single-Arm,Multicenter Phase, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents

Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC

Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer

Hitting KRAS G12D without the gut punch: Can immunotherapy make it last?

An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.

Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.

Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer

In the first clinical study of HRS-4642 combined with adebrelimab in previously treated patients with metastatic KRAS G12D-mutant pancreatic cancer, the chemotherapy-free regimen showed manageable safety and preliminary antitumor activity.

#AACR26 Perioperative adebrelimab (vs placebo) improved MPR (53.8% vs 18.4%) and pCR rates (31.1% vs 7.6%) with an OS trend (HR 0.57). ct...

Dr. Yi-Long Wu at #AACR26 with an update on perioperative adebrelimab plus chemotherapy for resectable NSCLC. Addition of adebrelimab (vs...

Interesting phase 3 data presented at #AACR26 showing the benefit of adding adebrelimab (anti-PDL1) + chemo to treat resectable stage II ...